Dr. Mona S. Jhaveri discusses the importance of Lung Cancer Awareness Month, recent breakthroughs in lung cancer, and more. Dr. Ofer Sharon, CEO of OncoHost, to discusses a predictive biomarker for irAEs in non-small cell lung cancer. Mark McDonough, CEO of ChromaCode, discusses an innovative, high-definition PCR assay for enhanced detection of NSCLC. In patients with metastatic nonsquamous NSCLC, pembrolizumab plus chemotherapy showed clinical efficacy. Asbestos exposure led to a higher incidence of asbestos-related lung cancers in naval personnel. Dr. Melissa Johnson, of Sarah Cannon, discusses lung cancer trials to keep an eye on and unmet needs in lung cancer. Arun Krishna, of AstraZeneca, spoke about the FLAURA2 trial, which showed the efficacy of Tagrisso in the treatment of NSCLC. Taxus chinensis has significant therapeutic potential in alleviating non-small cell lung cancer. Drs. Bo Wang and Sheena Bhalla discuss the EVOKE-02 study, which assessed sacituzumab govitecan plus pembrolizumab in NSCLC. BAP1 immunohistochemistry and p16 (CDKN2A) deletion contribute to providing a definitive diagnosis of mesothelioma. The ACS has released an update to its lung cancer screening guideline, which applies to nearly five million smokers. Risk model-based lung cancer screening may reduce racial and ethnic disparities and improve overall screening efficiency. Perioperative immunotherapy both before and after surgery significantly improves EFS in operable early-stage NSCLC. Immune evasion alterations impact the duration of response to checkpoint inhibitors in patients with metastatic NSCLC. Neoadjuvant pembrolizumab in combination with chemotherapy followed by resection and adjuvant pembro improves OS in NSCLC. Dostarlimab and chemotherapy combo demonstrates robust safety and efficacy in treating metastatic nonsquamous NSCLC. The FDA approved pembrolizumab for the neoadjuvant and adjuvant treatment of resectable non-small cell lung cancer. The FDA approved encorafenib with binimetinib for the treatment of adult patients with metastatic non-small cell lung cancer. A machine learning model that uses 3 variables can predict lung cancer risk and the need for screening. A liquid biopsy test may determine which patients with NSCLC benefit from targeted radiation.